Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention (Q38210809)

31 August 2017

Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention (English)

1 reference

31 August 2017

1 reference

1 reference

1

1 reference

31 August 2017

2

Luca Castellazzi

1 reference

31 August 2017

Annalisa Bosco

3

1 reference

PubMed ID

24815780

31 August 2017

Alessandra Musio

series ordinal

4

1 reference

PubMed ID

24815780

31 August 2017

Jeffrey Stoddard

series ordinal

5

1 reference

31 August 2017

1 January 2014

1 reference

31 August 2017

1 reference

31 August 2017

6

1 reference

31 August 2017

4

1 reference

31 August 2017

395-408

1 reference

Neisseria meningitidis serogroup B vaccine development

31 August 2017

1 reference

Global epidemiology of meningococcal disease.

21 January 2018

1 reference

Mechanisms of meningeal invasion by a bacterial extracellular pathogen, the example of Neisseria meningitidis.

21 January 2018

1 reference

Neisseria meningitidis: biology, microbiology, and epidemiology.

21 January 2018

1 reference

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

21 January 2018

1 reference

Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.

21 January 2018

1 reference

Review of meningococcal group B vaccines

21 January 2018

1 reference

Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination

21 January 2018

1 reference

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

21 January 2018

1 reference

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

21 January 2018

1 reference

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

21 January 2018

1 reference

Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningoc

21 January 2018

1 reference

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose

21 January 2018

1 reference

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.

21 January 2018

1 reference

Letter from the editor: field of vaccines and immunotherapeutics

21 January 2018

1 reference

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

21 January 2018

1 reference

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

21 January 2018

1 reference

Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines

21 January 2018

1 reference

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

21 January 2018

1 reference

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

21 January 2018

1 reference

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).

21 January 2018

1 reference

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

21 January 2018

1 reference

Genetic characteristics of Neisseria meningitidis serogroup B strains carried by adolescents living in Milan, Italy: implications for vaccine efficacy

21 January 2018

1 reference

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.14.11

1 reference

31 August 2017

1 reference

PubMed ID

24815780